Dr. Patnaik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4383 Medical Dr
San Antonio, TX 78229Phone+1 210-593-5700Fax+1 210-593-5992
Education & Training
University of Toronto Faculty of MedicineClass of 1992
Certifications & Licensure
TX State Medical License 2000 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
Clinical Trials
- A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02) Start of enrollment: 2007 May 01
- Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
- A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 514 citationsPhase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, S. Peter Kang, Drew W. Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap
Clinical Cancer Research. 2015-05-14 - 438 citationsFirst-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid TumorsTimothy A. Yap, Li Yan, Amita Patnaik, Ivy Fearen, David Olmos
Journal of Clinical Oncology. 2011-12-10 - 16 citationsEganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.David S Hong, Michael Postow, Bartosz Chmielowski, Ryan Sullivan, Amita Patnaik
Clinical Cancer Research. 2023-06-13
Press Mentions
selfBACK App Developed by Norwegian University of Science Can Help Relieve Back PainAugust 3rd, 2021- START Launches New Phase I Clinical Trial Program in UtahJune 8th, 2021
- Nektar Therapeutics Announces Its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)May 18th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
